| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP3636-5mg | 5mg | $296.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
136.4400
3.6505
3.6499
.0081
.4653
1.1140
Low
77.0325
7.0639
No
No
No
No
No
No
0.3
Yes
No
Yes
Yes
With the intensifying global population aging, the prevention and treatment of menopause-related diseases has become an important focus in medical research. Menopausal syndrome not only affects women's quality of life but is also closely linked to osteoporosis, cardiovascular diseases, and neuropsychiatric disorders. Although traditional drug treatments are effective, they have certain side effects and safety risks, prompting researchers to continuously explore safe and efficient candidate molecules in natural products. 26-Deoxycimicifugoside, a triterpene xylet compound isolated from Cimicifuga racemosa, has attracted widespread attention in recent years due to its unique structure and potential pharmacological activity. This paper aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, and druggability evaluation of 26-deoxycimicide, and to explore its application prospects in menopausal related diseases.
26-Deoxycimicide is a triterpene xylet glycoside with a complex molecular formula and a molecular weight of 658.8290. Its structural core is a triterpene backbone, connected to glycosyl groups, giving it high polarity and specific pharmacological activity. The LogP value was 3.6505, indicating moderate lipid solubility, which facilitates cell membrane penetration but has low water solubility (0.0081), posing challenges for bioavailability and formulation development. Its topological pole surface area (TPSA) is 136.44 Ų, suggesting that the molecule contains a high number of polar groups, which may affect its transmembrane transport and targeting capabilities. The low permeability of the blood-brain barrier indicates that it mainly acts on peripheral tissues, reducing the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0.3, indicating low genotoxicity risk and good safety.
26-Deoxycimicifuga mainly comes from Cimicifuga racemosa, a traditional herb widely distributed in North America and parts of Asia. The rhizomes of Cimicifuga contain abundant triterpenoids, especially xylogenic glycosides, which are the main source of its active components. Common methods for extracting 26-deoxycimicide include:
In recent years, supercritical CO₂ extraction and molecular blotting technologies have also been attempted for efficient extraction and purification of triterpene xylosides from cimicifuga, improving extraction efficiency and environmental friendliness.
The pharmacological activity of 26-deoxycimicide mainly focuses on regulating menopausal hormone levels and alleviating menopausal symptoms. Its main pharmacological effects include:
Additionally, 26-deoxycimicide exhibits antioxidant, anti-inflammatory, and neuroprotective effects, helping to alleviate common cardiovascular and neurological issues in menopausal women. Both in vitro cell models and animal experiments have confirmed its potential in improving bone density, regulating lipid metabolism, and neurobehavior.
The mechanism of action of 26-deoxycimarin is mainly achieved through multi-target coordinated regulation:
The synergistic effects of these targets enable 26-deoxycimicide to exhibit multiple pharmacological effects in regulating endocrine function, anti-inflammation, and protecting bones.
The druggability parameters of 26-deoxycimarin indicate that it has certain potential for drug development:
Pharmacokinetics, existing studies show that 26-deoxycimicmicriside is slowly absorbed orally and has a moderate plasma half-life, mainly metabolized and excreted by the liver. Its low water solubility and large molecular weight limit bioavailability, requiring advanced formulation technologies such as nanocarriers and liposomes to enhance in vivo stability and targeting.
Due to its unique pharmacological activity and good safety, 26-deoxycimicide has broad application prospects in the prevention and treatment of menopausal syndrome. Its estrogen-like effects can replace traditional hormone replacement therapies and reduce the risk of hormone-related side effects. Future research should focus on:
In addition, 26-deoxycimicide, as a representative natural product, is also in line with the trend of modern drug research and development for its green and sustainable development.
26-Deoxycimicide, as an important triterpene xylet glycoside in cimicifuga, exhibits multiple pharmacological activities such as regulating menopausal hormone levels, alleviating menopausal symptoms, and protecting the bone and cardiovascular systems. Its unique molecular structure and good safety profile provide both theoretical and practical basis for its role as a novel treatment for menopause. In the future, through in-depth mechanistic research and clinical validation, combined with advanced formulation technology, 26-deoxycimicide is expected to become a star molecule in the field of natural product pharmacology, offering a safe and effective treatment option for menopausal women.
